Physician profile
Jacqueline Squire
NPI 1710373758
$5,508.45
in general payments reported to CMS, 2019-2025
14 companies · $3,038 in 2025
The $3,038 reported for 2025 was more than what 81% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2021: $226 · 2022: $297 · 2023: $682 · 2024: $901 · 2025: $3,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889 · Consulting Fee: $1,719 · Travel and Lodging: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,889.32 |
| Consulting Fee | $1,719.00 |
| Travel and Lodging | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,238.47 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $732.61 | 2022-2024 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $501.81 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $382.92 | 2023-2025 | |
| Csl Behring | $264.16 | 2021-2025 | Andembry, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $208.05 | 2021 | |
| Biocryst US Sales Co., LLC | $148.93 | 2025 | Orladeyo |
| Blueprint Medicines Corporation | $147.61 | 2024 | |
| Adma Biomanufacturing LLC | $125.00 | 2025 | |
| Genentech USA, INC. | $125.00 | 2019 | |
| Kedrion Biopharma, INC. | $120.00 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Horizon Therapeutics Plc | $117.15 | 2023 | Actimmune |
| Glaxosmithkline, LLC. | $95.08 | 2022 | |
| Sobi, INC | $62.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Squire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.